Ramipril in patients with arterial hypertension as monotherapy or in combination with hydrochlorothiazide

Yu.M. Sirenko, О.L. Rekovets

Abstract


Today, there is developed the effective antihypertensive therapy, which significantly reduces the risk of cardiovascular events in patients with hypertension. One of the objectives of hypertension treatment is to ensure the control of the blood pressure below target levels, thereby reducing the risk of cardiovascular morbidity and mortality. The use of angiotensin-converting enzyme inhibitors is justified because of the high efficacy in the treatment and prevention of hypertension, heart failure, kidney disease, as well as diabetic nephropathy. Basic researches on the study of antihypertensive efficacy and safety of ramipril in patients with mild to moderate hypertension have shown the benefits of its administration as the drug of choice in these patients. Diuretics, as a class, were almost ideal agents, if it is necessary to prescribe other drug, as they potentiate the action of agents of all other classes. Therefore, the combination of ramipril with hydrochlorothiazide may be considered as one of the best in the treatment of patients with hypertension.


Keywords


ramipril; hydrochlorothiazide; arterial hypertension

References


Багрий А.Э., Сиренко Ю.Н. и др. Антигипертензивная эффективность и переносимость фиксированной комбинации рамиприла и гидрохлоротиазида (характеристика протокола и предварительные данные многоцентрового проспективного исследования СТАРТ) // УКЖ. — 2009. — № 3. — С. 39-43.

Звершхановський Ф.А., Доскоч Є.З., Гупало А.А., Левицька Л.О., Лазарчук Л.М., Майка Л.К. Вплив препарату раміприл на структурно-функціональне ремоделювання міокарда у хворих на гіпертонічну хворобу // Медицина транс­порту України. — 2010. — № 3. — С. 46-48.

Радченко Г.Д., Торбас О.О., Доброход А.С., Сіренко Ю.М., Поліщук С.А. Оцінка антигіпертензивної ефективності та впливу на жорсткість артерій раміприлу (Рамізес), призначеного у вигляді монотерапії або в комбінації з амлодипіном (Аладин), у пацієнтів з м’якою та помірною артеріальною гіпертензією // Артеріальна гіпертензія. — 2013. — № 5. — С. 41-51

Сиренко Ю.Н., Рековец О.Л., Андриевская С.А., Бабак О.Я., Говорова О.В., Рудык Ю.С. Aнтигипертензивная эффективность рамиприла у больных мягкой и умеренной артериальной гипертензией (результаты многоцентрового исследования «RASH» — RAmipril Study in patient with arterial Hypertension) // Український кардіологічний журнал. — 2007. — № 1. — С. 41-47.

Сіренко Ю.М. Артеріальна гіпертензія. — К.: Моріон, 2002. — 204 с.

Ханюков А.А. Эффективность и безопасность комбинированной антигипертензивной терапии в комплексном лечении пациентов с артериальной гипертензией и хронической обструктивной болезнью легких // Webcardio.org. — 2015.

Чуба Л.І., Винниченко Л.Б. Застосування схем комбінованої терапії у хворих на артеріальну гіпертензію високого і досить високого ризику // Вісник СумДУ. — 2008. — Т. 2, № 2.

ACCORD Study Group, Cushman W.C., Evans G.W., Byin­gton R.P., Goff D.C. Jr, Grimm R.H. Jr, Cutler J.A., Simons-Morton D.G., Basile J.N., Corson M.A., Probstfield J.L., Katz L., Peterson K.A., Friedewald W.T., Buse J.B., Bigger J.T., Gerstein H.C., Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. — 2010. — Vol. 29. — P. 1575-1585.

Ahimastos A.A., Walker P.J., Askew C., Leicht A., Pappas E., Blombery P., Reid C.M., Golledge J., Kingwell B.A. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a rando­mized controlled trial // JAMA. — 2013. — Vol. 309(5). — P. 453-460.

Bakris G.L., Gaxiola E., Messerli F.H. et al. INVEST Investigators. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril study // Hypertension. — 2004. — № 44(5). — Р. 637-642.

Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., Stoyanovsky V., Antikainen R.L., Nikitin Y., Anderson C., Belhani A., Forette F., Rajkumar C., ­Thijs L., Banya W., Bulpitt C.J.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358. — P. 1887-1898.

Bhushan B., Gupta S., Khajuria V., Kumar D., Lal M., Kumar D., Bhat S., Sharma A. Comparative efficacy and safety of triple therapy (ramipril, telmisartan, hydrochlorothiazide) vs dual antihypertensive therapy (ramipril or telmisartan, hydrochlorothiazide) in stage 2 hypertensive patients // J. Clin. Diagn. Res. — 2014. — № 8(8). — HC25-28.

Brenner B., Cooper M., Zeeuw D. еt al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. — 2001. — Vol. 345. — P. 861-869.

Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U. for the LIFE investigators. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359. — P. 995-1003.

Degl’Innocenti A., Elmfeldt D., Hansson L., Breteler M., James O., Lithell H., Olofsson B., Skoog I., Trenkwalder P., Zanchetti A., Wiklund I. Cognitive function and health-related quality of life in elderly pa- tients with hypertension –baseline data from the study on cognition and prognosis in the elderly (SCOPE) // Blood Press. — 2002. — Vol. 11(3). — P. 157-165.

Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlorthalidone reduces cardiovascular events compared with hy- drochlorothiazide. A retrospective cohort analysis // Hypertension. — 2011. — Vol. 57. — P. 689-694.

Genthon R. Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group // Int. J. Clin. Pharmacol. Res. — 1994. — 14(1). — 1-9.

Guidelines Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. — 2003. — Vol. 21. — P. 1011-1053

Hansson L., Hender T. Hypertension Manual 2000. — Layout Bohlin Production AB, 2000. — 128 p.

Hansson L., Zanchetti A., Carruthers S. et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. — 1998. — Vol. 351. — P.17-55-1762

Heidbreder D., Froer K.L., Breitstadt A., Cairns V., Langley A., Bender N. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1. A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy // Clin. Cardiol. — 992 Dec. — 15(12). — 904-910.

Hypertension Primer. The essentials of high blood pressure. From the council on high blood pressure research / American Heart Association. — 1999. — 471 p.

Jamerson K., Weber M.A., Bakris G.L., Dahlöf B., Pitt B., Shi V., Hester A., Gupte J., Gatlin M., Velazquez E.J.; ACCOMPLISH Trial Investigators.. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2417-2428.

Kim S.H., Chung W.Y., Zo J.H., Kim M.A., Chang H.J., Cho Y.S., Youn T.J., Chae I.H., Choi D.J., Gwak J.J., Lee H.Y., Park J.S., Kang H.J., Kim Y.J., Kim H.S. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial // Clin. Ther. — 2009. — № 31(5). — Р. 988-998.

Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Boudier H.A., Zanchetti A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J.L., Erdine S., Kiowski W., Agabiti-Rosei E., Ambrosioni E., Lindholm L.H., Viigimaa M., Adamopoulos S., Agabiti-Rosei E., Ambrosioni E., Bertomeu V., Clement D., Erdine S., Farsang C., Gaita D., Lip G., Mallion J.M., Manolis A.J., Nilsson P.M., O’Brien E., Ponikowski P., Redon J., Ruschitzka F., Tamargo J., van Zwie­ten P., Waeber B., Williams B.; Management of Arterial Hypertension of the European Society of Hypertension; European Socie­ty of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Forcefor the Managementof Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. — 2007. — Vol. 25. — P. 1105-1187.

Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J., Cifkova R., Clément D., Coca A., Dominiczak A., Erdine S., Fagard R., Farsang C., Grassi G., Haller H., Heagerty A., Kjeldsen S.E., Kiowski W., Mallion J.M., Manolis A., Narkiewicz K., Nilsson P., Olsen M.H., Rahn K.H., Redon J., Rodicio J., Ruilope L., Schmieder R.E., Struijker-­Boudier H.A., van Zwieten P.A., Viigimaa M., Zanchetti A.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27. — P. 2121-2158.

Мancia G., Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis // J. Hypertens. — 2004. — Vol. 22. — P. 435-445

Matsuzaki M., Ogihara T., Umemoto S., Rakugi H., Matsuoka H., Shimada K., Abe K., Suzuki N., Eto T., Higaki J., Ito S., Kamiya A., Kikuchi K., Suzuki H., Tei C., Ohashi Y., Saruta T.; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group.Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial // J. Hypertens. — 2011. — Vol. 29. — P. 1649-1659.

Messerli F.H., Banglore S. Half century of hydrochlorothiazide: facts, fads, fiction, and follies // Am. J. Med. — 2011. — Vol. 124. — P. 896-899.

Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A Meta-Analysis of Randomized Trials // J. Am. Coll. Cardiol. — 2011. — Vol. 57. — P. 590-600.

Oigman W., Gomes M.A., Pereira-Barretto A.C., Póvoa R., Kohlmann O., Rocha J.C., Nobre F. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM // Clin. Ther. — 2013. — № 35(5). — 702-10.

Pessina A.C., Rossi G.P. Very-low-dose combination the­rapy in hypertension. — London: Science Press Ltd, 2002. — 50 p.

PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack // Lancet. — 2001. — Vol. 358. — P. 1033-1041.

Schrader J., Lüders S., Kulschewski A., Hammer­sen F., Plate K., Berger J., Zidek W., Dominiak P., Diener H.C.; MOSES Study Group: MOSES — Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention // Stroke. — 2005. — Vol. 36. — P. 1218-1226.

Spinar J., Vitovec J., Soucek M., Dusek L., Pavlik T. CORD: comparison of recommended doses of ace inhibitors and angiotensin II receptor blockers // Int. J. Cardiol. — 2009. — Vol. 144. — P. 293-294.

Spinara J., Vitovec J., Soucek M. Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study) // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. — 2014 — Vol. 158(3). — P. 412-421.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attacck Trial // JAMA. — 2002. — Vol. 288. — P. 2981-2997.

The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // NEJM. — 2008. — Vol. 358. — P. 1547-1559.

Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration // Lancet. — 2003. — Vol. 8, 362(9395). — P. 1527-1535.

Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 tr als. // Am. J. Med. — 2009. — Vol. 122. — P. 290-300.

White W. Blood pressure monitoring in cardiovascular medicine and therapeutics. — New Jersey: Humana Press, 2001. — 309 p.

Young J.H., Klag M.J., Muntner P., Whyte J.L., Pahor M., Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP) // J. Am. Soc. Nephrol. — 2002 — Vol. 13(11). — P. 2776-2782.

Sumner G., Salehian O., Yi Q., Healey J., Mathew J., ­Al-Merri K., Al-Nemer K., Mann J.F., Dagenais G., Lonn E.; HOPE Investigators. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial // J. Cardiovasc. Electrophysiol. — 2009. — Vol. 20(7). — P. 781-787.

McQueen M.J., Lonn E., Gerstein H.C., Bosch J., Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences // Scand J. Clin. Lab. Invest. Suppl. — 2005. — Vol. 240. — P. 143-156.




DOI: https://doi.org/10.22141/2224-1485.1.51.2017.96253

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru